- Game-changing weekly semaglutide therapy launched at unprecedented affordability
- ‘SUNDAE’ aims to bring advanced GLP-1 treatment within reach of 70% of patients
- Multi-dose vials now; convenient pen-device rollout slated for April
- Big leap in tackling India’s twin epidemics—Type 2 Diabetes & obesity
NE HEALTH BUREAU
AHMEDABAD, MAR 20
In a landmark move set to reshape diabetes care in India, Eris Lifesciences has unveiled a highly affordable version of Semaglutide under the brand ‘SUNDAE’, bringing one of the world’s most advanced therapies within reach of millions.
Priced starting at just ₹220 per weekly shot—and approximately ₹1,290 per month for multi-dose vial formats—the launch marks a decisive step toward democratizing access to cutting-edge treatment for Type 2 Diabetes, a condition affecting a rapidly growing population in India.
Semaglutide, a GLP-1 receptor agonist, has globally redefined diabetes and weight management by delivering superior glycaemic control alongside meaningful weight reduction—two critical factors in managing metabolic health. With rising obesity levels compounding diabetes risks, such therapies are increasingly seen as transformative.
Eris’ ‘SUNDAE’ is being introduced in 2 mg/1.5 ml and 4 mg/3 ml vial formats, with plans to roll out a user-friendly pen device in April. The pen will be priced between ₹4,000 and ₹4,500 per month across dosage strengths, further enhancing patient convenience and adherence.
Advanced, evidence-based therapies accessible for all
“Semaglutide represents a breakthrough in the management of diabetes and metabolic disorders, with the potential to significantly improve patient outcomes. With the launch of SUNDAE, we are fulfilling our responsibility to make such advanced therapies truly accessible and affordable to a much larger patient population.”
“This reflects our continued commitment to strengthening our diabetes portfolio with high-impact, patient-centric solutions, while leveraging our strong presence in chronic care to drive rapid adoption and expand access across India.”
“We have been proactively preparing to unlock the GLP-1 opportunity in a meaningful way, and this initiative marks an important step in democratizing access to innovative therapies.”
“We believe it will not only help address the growing diabetes burden in the country but also serve as a key driver of sustainable, long-term value creation for Eris.”
Backed by its strong engagement with diabetologists nationwide, Eris is positioning itself at the forefront of next-generation metabolic care. The introduction of semaglutide significantly strengthens its portfolio and aligns with global treatment trends that prioritise both glucose control and weight management.
With India often dubbed the diabetes capital of the world, this move could mark a turning point—making advanced, evidence-based therapies accessible not just to a select few, but to the masses who need them most.
